[KO Validated] Anti-HER2/ErbB2 Polyclonal Antibody for WB, ELISA - P04626

Core Product Specifications and Parameters

Biological Background: HER2/ErbB2 Function and Localization

• HER2/ErbB2 is a receptor tyrosine-protein kinase encoded by the ERBB2 gene (GeneID: 2064) and is a member of the epidermal growth factor receptor (EGFR/ErbB) family. The full-length protein is a single-pass type I membrane protein of 1255 amino acids, with a predicted molecular weight of 137.9 kDa (observed at approximately 138 kDa).
• It functions as a coreceptor in neuregulin-receptor complexes, essential for ligand-dependent signaling, but requires heterodimerization with other ErbB family members (e.g., EGFR, ErbB3, ErbB4) for high-affinity ligand binding and kinase activation.
• HER2 signaling regulates outgrowth and stabilization of peripheral microtubules via the MEMO1-RHOA-DIAPH1 pathway, inhibiting GSK3B and promoting membrane association of APC and CLASP2, which in turn facilitates microtubule capture and stabilization.
• In the nucleus, HER2 acts as a transcriptional regulator, binding to the PTGS2/COX-2 promoter (5’-TCAAATTC-3’ sequence) to activate transcription, and also promotes CDKN1A expression through STAT3 and SRC involvement, as well as rRNA gene transcription by RNA Pol I, enhancing protein synthesis and cell growth.
• Subcellular localization includes the cell membrane, ruffle membrane, early endosome, cytoplasm (perinuclear region), and nucleus, reflecting its diverse signaling and transcriptional roles.
• HER2 is overexpressed in a variety of tumor tissues, including primary breast, small bowel, esophageal, renal, and oral cancers, making it a critical biomarker and therapeutic target.
• Key post-translational modifications include phosphorylation (phosphoprotein) and glycosylation; the protein also features a signal peptide, disulfide bonds, and alternative initiation and splicing isoforms.
• UniProt keywords highlight its biological roles: activator, alternative splicing, ATP-binding, cell membrane, disease variant, kinase, receptor, signal, transcription regulation, transferase, transmembrane.

Experimental Guidance and Technical Tips

• The immunogen sequence (aa 1156–1255) is located in the C-terminal cytoplasmic domain of HER2; therefore, this antibody is expected to recognize the full-length form (~138 kDa) in Western blot (WB), with potential detection of truncated or alternatively spliced isoforms if they retain this epitope.
• For WB, use reducing conditions; the glycosylated and phosphorylated mature protein may migrate slightly higher. Validate the band specificity using HER2-positive and -negative cell lines (e.g., SK-BR-3 vs. MCF-7) and, if available, KO-validated lysates as indicated by the product validation.
• In ELISA applications, consider using peptide coating or direct antigen capture due to the intracellular epitope. Optimize coating conditions and antibody dilutions in relevant sample matrices.
• Due to high expression in tumors, lysates from breast cancer cell lines or tumor tissues may produce strong signals; include appropriate loading controls and normalize to total protein.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your comprehensive B2B partner for IVD raw materials, supporting diagnostic manufacturers, clinical laboratories, and research institutes from concept to clinic. With this anti-HER2/ErbB2 polyclonal antibody, we provide a reliable reagent for oncology biomarker research, assay development, and companion diagnostics. Beyond antibodies, our portfolio includes validated antibody pairs, monoclonal/polyclonal options, bulk ancillary reagents, and rare target sourcing services, ensuring your project’s success with streamlined access to critical materials.